REVISÃO SISTEMÁTICA SOBRE INVESTIGAÇÕES IN VITRO VOLTADAS PARA O TRATAMENTO DA TUBERCULOSE RESISTENTE E MULTIDROGA-RESISTENTE [PDF]
, 2021 Introduction: Tuberculosis is caused by variants of the Mycobacterium tuberculosis species, mainly affecting immunocompromised individuals. In this sense, the tuberculosis bacillus in its multi-resistant (MDR) and extremely resistant (XDR) forms has ...
Rocha Pinheiro Machado, Rachel +2 more
core +2 more sources
Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children [PDF]
, 2023 Tuberculosis (TB) is a major public health problem, with nearly 10 million new cases and millions of deaths each year. Around 10% of these cases are in children, but only a fraction receive proper diagnosis and treatment. The spread of drug-resistant (DR)
Hanzhao Zhu +9 more
core +1 more source
Targeting the serine pathway:a promising approach against tuberculosis? [PDF]
, 2019 Tuberculosis is still the leading cause of death by a single infectious agent. Effective chemotherapy has been used and improved since the 1950s, but strains resistant to this therapy and most antibacterial drugs on the market are emerging.
Haufroid, Marie, Wouters, Johan
core +1 more source
Treatment optimisation of multidrug-resistant tuberculosis [PDF]
, 2023 A successful treatment outcome is seen in only 60% of persons treated for multidrugresistant tuberculosis (MDR-TB) worldwide, defined as resistance to both rifampicin and isoniazid.
Kuhlin, Johanna
core +1 more source
Candidate anti-tuberculosis medicines and regimens under clinical evaluation [PDF]
Background: Tuberculosis (TB) is the leading cause of mortality by an infectious disease worldwide. Despite national and international efforts, the world is not on track to end TB by 2030.
Barros-Aguirre, David +7 more
core +1 more source
Investigational and Experimental Drugs for Community-Acquired Pneumonia: the Current Evidence
Journal of Experimental Pharmacology, 2020 Juilia Sellarès-Nadal, Joaquin Burgos, Vicenç Falcó, Benito Almirante Infectious Diseases Department, Hospital Universitari Vall d’Hebron, Autonomous University of Barcelona, Barcelona, SpainCorrespondence: Benito ...
Sellarès-Nadal J +3 more
doaj
The development of a flow route to synthesize 3- benzyl-6-bromo-2-methoxyquinoline, an intermediate of an anti-TB drug, bedaquilin [PDF]
, 2022 SA has a high number of reported cases of multidrug-resistant tuberculosis (MDR-TB). Bedaquiline is a newly approved active ingredient of an anti-tuberculosis drug with high potency against MDR-TB.
Mpalala, Anele
core +1 more source
Oxazolidinones as versatile scaffolds in medicinal chemistry [PDF]
, 2023 Oxazolidinone is a five-member heterocyclic ring with several biological applications in medicinal chemistry. Among the three possible isomers, 2-oxazolidinone is the most investigated in drug discovery. Linezolid was pioneered as the first approved drug
Castagnolo, Daniele +4 more
core
Evolución clínico - epidemiológica de la tuberculosis en pacientes del centro de salud San Luis, Lima 2018-2022 [PDF]
, 2022 Objetivo: Detallar la evolución de la Tuberculosis (TB) en pacientes de Centro de Salud San Luis y sus características clínico-epidemiológicas. Material y Métodos: Fue un estudio de tipo observacional, descriptivo, transversal, retrospectivo. Se evaluó
Moreno Ayala, Morelia Ivett
core
Role for Linezolid in drug sensitive tuberculosis [PDF]
Tuberculosis (TB) continues to be a global challenge. Reducing the duration of TB treatment for drugsensitive TB (DSTB) has direct and distinct advantages.
Narendran, G +2 more
core +1 more source